CG
CTIC

Caprock Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Caprock Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,000
Closed -$61K – 388
2016
Q4 		$61K Buy
+15,000
New +$62.2K 0.02% 337

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caprock Group's CTIC Position: Q1 2017 in Review

Caprock Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2017, closing a stake of 15,000 shares — an estimated $61K sold.

Caprock Group first reported a position in CTIC in Q4 2016 and held it in 1 quarter. The position peaked at $61K in Q4 2016. 47 funds tracked by Wall St. Rank hold CTIC as of Q1 2017.

  • Caprock Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2017 after selling out during the quarter.
  • Caprock Group sold 15,000 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2017, an estimated $61K.
  • Caprock Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2016 and held it in 1 quarter.
  • Caprock Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $61K in Q4 2016.
  • 47 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2017.

Based on Caprock Group's 13F filing for Q1 2017, filed 21 Apr 2017.